Clinical Trial Update: Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating biweekly intraperitoneal oxaliplatin with systemic capecitabine and bevacizumab for peritoneal carcinomatosis arising from app…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Appendiceal Cancer
• Colorectal Cancer
• Peritoneal Carcinomatosis

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING